• Make it like cafepharma, but for different industries: over the years we’ve had suggestions for creating a site similar to cafepharma, but for different industries. Now there is a place. Check out CompanyUnderground for company forums in other industries. Don’t see a company? Request it here. Let your friends and family outside the pharma/medical sales space know they now have a safe, anonymous place to talk.


JJ

Quote












Pauls did what he did, but was JJ at all qualified to head SRM to begin with? Lets put a development guy with no proven business success in charge of a $750M acquisition/investment. Monday morning quarterbacking is easy, but even a bus admin freshman would have made a better choice. In fact, take a look at all the SRM exec management Shire put in charge across the board and draw your own conclusions.
 






Was the head of regenerative medicine at Shire Pharmaceuticals fooled into accepting a promotion? Jeff Jonas claims in a lawsuit that the biotech failed to disclose the unit faced declining sales, a probe by the feds into illegal marketing and that a new Shire ceo was about to be named right after he began his new job. Had he known all this, Jones maintains he would have instead taken another job offer.

The mess began last fall, when Jonas approached former Shire ceo Angus Russell about his desire for a position with added responsibilities since he was being offered such opportunity elsewhere. And so, last November he was named president of regenerative medicine and moved from Philadelphia to San Diego, where the unit was based, according to the lawsuit.

He did so after receiving assurances that his position would be secure under newly named Shire ceo Flemming Ornskov and his skills were “urgently” needed. By early this year, however, he claims to have smelled a rat. For one, Ornskov allegedly began overhauling senior management and executives who were over 40 years old were being told they did not have “enough runway” to be offered promotions.

Moreover, Jonas claims to have belatedly learned that the US Department of Justice was investigating the unit, which was once Advanced Biohealing, a company that Shire had purchased in 2011. Its primary product was Dermagraft, which is used to treat diabetic foot ulcers. The feds were probing sales and marketing activities before and after the acquisition and, according to the lawsuit, were seeking up to $1.5 billion in penalties.

“As a number of significant employees left the RM business in the course of the DOJ investigation, it became clear to Jonas that he had been promoted to put a good face on a messy, problematic situation in RM business, rather than to use his skills to build the division, as senior management had previously represented,” he claims in his lawsuit.

Jonas claims to have heard rumors that he was to be replaced in connection with the age-related management overhaul and, after raising concerns, he was demoted last month and placed on administrative leave. He alleges these moves sullied his reputation inside and outside the biotech and this constituted wrongful termination. His age, by the way, is not disclosed in the lawsuit
 






Whether or not the principle applies --sales were rolling prior to Shire stepping in and sticking their dirty noses in our business in May 2012. May 2012 was comparable to the Wall Street crash around here..
 






Top Bottom
Back
Quote